LFG
NPCE icon

Larson Financial Group’s Neuropace NPCE Stock Holding History

Larson Financial Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13K Buy
71
+44
+163% +$708 ﹤0.01% 3270
2026
Q1 		$355 Buy
27
+16
+145% +$240 ﹤0.01% 3379
2025
Q4 		$170 Buy
+11
New +$147 ﹤0.01% 3293
2025
Q3 		– Sell
-1,033
Closed -$11.5K – 3578
2025
Q2 		$11.5K Buy
1,033
+7
+0.7% +$88 ﹤0.01% 1743
2025
Q1 		$12.6K Buy
+1,026
New +$12.8K ﹤0.01% 1548

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Larson Financial Group's NPCE Position: Q2 2026 in Review

Larson Financial Group increased its Neuropace (NPCE) stake by 163% in Q2 2026, buying an estimated $708 and bringing the position to 71 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #3270.

Larson Financial Group first reported a position in NPCE in Q1 2025 and has held it in 5 quarters since. The position peaked at $12.6K in Q1 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Larson Financial Group held 71 shares of Neuropace worth $1.13K as of Q2 2026.
  • Larson Financial Group bought 44 Neuropace shares in Q2 2026, an estimated $708.
  • Neuropace made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3270 holding.
  • Larson Financial Group first reported a position in Neuropace in Q1 2025 and has held it in 5 quarters since.
  • Larson Financial Group's Neuropace position peaked at $12.6K in Q1 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.